Long COVID & ME/CFS

Long COVID (Post-Acute Sequelae of SARS-CoV-2 / PASC) and ME/CFS are now understood to share extensive biological mechanisms. Studies show widely varying overlap depending on population and diagnostic criteria. A Japanese outpatient clinic study found 8.4% of long COVID patients met ME/CFS criteria (Morita et al., PLOS ONE 2024, n=739), while a US community-based survey found 58% of long COVID patients met ME/CFS case definitions (Jason et al. 2023, n=465). The large NIH RECOVER study (n=13,000) found 4.5% of all COVID-19 patients subsequently developed ME/CFS - compared to only 0.6% of uninfected controls, a hazard ratio of nearly 5. Clinical samples capturing more severely ill patients tend to show higher rates.^[4] The PNAS 2025 Komaroff et al. study of 3,900+ patients found significant overlap in symptom profiles and treatment responses between ME/CFS and long COVID.^[36]

Shared mechanisms documented in both conditions:

• GPCR autoantibodies (beta-2 adrenergic, muscarinic)^[12]
• Mitochondrial dysfunction (WASF3 pathway)^[10]
• Fibrin amyloid microclot formation^[19]
• Gut dysbiosis and increased intestinal permeability^[20,21]
• Neuroinflammation and brain fog^[14,15]
• POTS and dysautonomia
• Impaired NK cell function^[13]

Many researchers consider long COVID to have substantially expanded ME/CFS research capacity, and expect cross-fertilization of research to accelerate treatment development for both conditions. The NIH RECOVER Initiative is the largest such program.^[9]

Post-Treatment Lyme Disease Syndrome (PTLDS) - persistent fatigue, pain, and cognitive symptoms after antibiotic-treated Lyme disease - meets ME/CFS criteria in many patients. Borrelia burgdorferi is one of the documented triggers of ME/CFS per prospective cohort data.^[34,35]

Key distinctions and evidence:

• PTLDS requires documented prior Lyme infection by CDC two-tier serological criteria
• Three NIH-funded RCTs found that prolonged antibiotic therapy is not more effective than placebo in PTLDS and carries significant risks^[53]
• The same pacing and symptom management principles apply as in ME/CFS
• "Chronic Lyme disease" as described by some practitioners without PTLDS criteria lacks a consistent validated scientific definition
• Seronegative Lyme is scientifically controversial; most major guidelines do not support this diagnosis

Epstein-Barr virus (the mono virus) is the best-documented ME/CFS trigger. The Hickie et al. landmark prospective cohort study (BMJ 2006) found approximately 12% of people developed a ME/CFS-like syndrome six months after acute EBV infection.^[34] Multiple subsequent cohort studies have replicated this finding. EBV-triggered ME/CFS may involve persistent viral latency and periodic reactivation due to impaired NK cell surveillance.^[13]

• Mono in adolescents carries a higher risk of post-infectious ME/CFS than in adults
• EBV serology panel (VCA IgG/IgM, EA-D, EBNA) should be part of ME/CFS workup
• Valacyclovir has been used in EBV-associated ME/CFS in small open-label studies; no large RCT exists
• Impaired NK cell function (not count) is the likely mechanism allowing EBV reactivation^[13]

Influenza and viral gastroenteritis (often caused by norovirus, rotavirus, or enteroviruses) can trigger ME/CFS in susceptible individuals, as demonstrated by the Hickie et al. prospective cohort which used multiple pathogen types.^[34] Enteroviral ME/CFS was recognized in historical epidemic outbreaks (e.g., Royal Free Disease, London, 1955; Lake Tahoe outbreak, 1984-1985).

• Influenza vaccination is generally recommended for ME/CFS patients to avoid a potential new infection trigger
• Enteroviral persistence in gut and cardiac tissue has been proposed as a mechanism but remains unproven
• Post-GI viral ME/CFS may relate to gut-brain axis disruption and microbiome changes^[20,21]
• The Hickie et al. study found post-infectious ME/CFS rates were similar (~12%) across EBV, Ross River virus, and Coxiella, suggesting host susceptibility is as important as pathogen identity^[34]

Studies show a large proportion of ME/CFS patients - estimated 35-70% depending on criteria used - also meet fibromyalgia diagnostic criteria, and vice versa.^[26] Both involve central sensitization, widespread pain, sleep dysfunction, and cognitive symptoms. Key distinction: PEM is the defining feature of ME/CFS and is not required for fibromyalgia. Both may involve small fiber neuropathy in a subset of patients.^[17]

• Shared treatments: low-dose TCAs, gabapentin/pregabalin, gentle paced movement
• FDA-approved fibromyalgia drugs (pregabalin, duloxetine, milnacipran) may help ME/CFS patients with significant pain
• Low-dose cyclobenzaprine (Tonmya) received FDA approval for fibromyalgia in 2023
• Both involve central sensitization but ME/CFS has distinct immune and mitochondrial pathology

Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD) are frequently reported alongside ME/CFS, POTS and mast cell activation syndrome, a clustering patients and clinicians often call the "trifecta." The best-documented part of that picture is the link between hypermobility and autonomic dysfunction: in a controlled study of joint hypermobility syndrome, 78% of patients (21 of 27) had orthostatic hypotension, POTS or uncategorised orthostatic intolerance on autonomic testing, compared with 10% (2 of 21) of controls, alongside heightened responsiveness to both alpha- and beta-adrenergic stimulation. The authors concluded that dysautonomia is an extra-articular manifestation of hypermobility rather than a coincidental association.^[54]

• MCAS, POTS/dysautonomia, and hEDS frequently cluster together
• Beighton score for hypermobility screening
• Physical therapy focuses on joint stabilization, not stretching
• Shared MCAS management strategies apply across all three

Dysautonomia is dysfunction of the autonomic nervous system (ANS) - the system that controls involuntary body functions including heart rate, blood pressure, digestion, sweating, and temperature. It is not a single disease but an umbrella term covering dozens of specific conditions. In ME/CFS, dysautonomia is present in the majority of patients and is one of the most underdiagnosed aspects of the illness.^[16]

Relationship to ME/CFS: Dysautonomia in ME/CFS is not incidental - it is mechanistically embedded in the disease. The same biological abnormalities that drive ME/CFS (GPCR autoantibodies, small fiber neuropathy, neuroinflammation, microvascular dysfunction) directly impair autonomic nerve signaling and regulation. Dysautonomia is both a consequence of these mechanisms and a driver of further symptoms through impaired cerebral perfusion, inappropriate sympathetic activation, and failure to regulate energy delivery to tissues.

Specific dysautonomia syndromes in ME/CFS:

• POTS (Postural Orthostatic Tachycardia Syndrome) - heart rate rises 30+ bpm within 10 minutes of standing; dizziness, palpitations, brain fog, fatigue; diagnosed by tilt table test or NASA lean test^[16]
• Neurally Mediated Hypotension (NMH) - blood pressure drops suddenly on prolonged standing; presyncope or fainting; distinct from POTS but often co-occurring
• Orthostatic Hypotension (OH) - sustained BP drop of 20+ mmHg systolic within 3 minutes of standing
• Hyperadrenergic POTS - a subset where excessive norepinephrine release drives the tachycardia; may respond differently to medications
• Cerebral hypoperfusion - reduced blood flow to the brain when upright, directly causing brain fog and cognitive worsening with standing^[112]
• Autonomic GI dysfunction - gastroparesis, abnormal gut motility, nausea driven by ANS dysregulation rather than primary GI disease
• Thermoregulatory dysfunction - inability to maintain normal body temperature; low-grade fevers, heat intolerance, cold extremities

Critically underdiagnosed: Many ME/CFS patients have never had a tilt table test or even a simple 10-minute standing test. Dysautonomia symptoms are frequently attributed to anxiety or deconditioning, delaying appropriate treatment by years. Treating dysautonomia - even when ME/CFS cannot yet be cured - can meaningfully reduce symptom burden and improve daily function.^[26]

Dysautonomia International (dysautonomiainternational.org) is a key patient advocacy and research organization covering POTS and related conditions.